Every 10-Q that DOCGO INC (DCGO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow DCGO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DCGO filings page.
DocGo Inc. reported lower results for the six months ended June 30, 2026. Revenues were $148.98 million, down from $176.45 million a year earlier, driven in part by non-renewal of large municipal migrant-related contracts. The company generated a net loss of $34.69 million versus $24.37 million in the prior-year period, and operating cash flow swung to an outflow of $13.90 million from an inflow of $43.26 million.
At June 30, 2026 DocGo held $25.23 million of cash and cash equivalents, $6.94 million of restricted cash and $15.90 million of restricted investments, with working capital of $47.46 million. Total assets were $186.82 million and total stockholders’ equity was $95.78 million.
The company disclosed it is out of compliance with a minimum liquidity covenant under its credit agreement and is in discussions with its lender to resolve the issue and preserve access to its credit facility, while also exploring a replacement term loan. Management noted ongoing operating losses and detailed cost-reduction and cash-preservation plans, and stated it believes these plans, when implemented, will be sufficient to alleviate substantial doubt about DocGo’s ability to continue as a going concern over the next twelve months.
DocGo Inc. reported Q1 2026 results with lower revenue and a wider net loss, alongside liquidity and covenant challenges. Revenue fell to $75.6 million from $96.0 million a year earlier, while the net loss attributable to stockholders increased to $14.8 million from $9.4 million, or $(0.15) per share versus $(0.09). Operating cash flow swung to an outflow of $4.7 million from an inflow of $9.2 million. Cash and cash equivalents declined to $35.7 million, with working capital of $60.9 million. The company discloses prior non-compliance with a minimum liquidity covenant under its credit agreement and is in discussions with its lender, while management has adopted cost-cutting and cash-preservation plans and believes these are sufficient to alleviate substantial doubt about its ability to continue as a going concern over the next 12 months.
DocGo (DCGO) reported a sharp year-over-year contraction in Q3 2025. Revenue was $70.8M versus $138.7M a year ago, driven by a steep drop in Mobile Health Services to $20.7M from $90.7M, while Transportation Services delivered $50.1M vs $48.0M. The company posted a net loss attributable to stockholders of $27.8M compared with $5.5M income a year earlier, reflecting lower volume and non-cash charges.
Management recorded a $8.7M goodwill impairment tied to the Rapid Temps reporting unit and a $8.0M impairment of finite‑lived intangibles in Mobile Health Services. For the nine months, revenue was $247.3M vs $495.7M, with a $48.3M loss to stockholders. Cash from operations was $44.9M, supported by a large reduction in accounts receivable. The balance sheet showed cash and cash equivalents of $73.4M, total assets of $353.8M, and no outstanding line of credit at quarter‑end. Shares outstanding were 97,813,372 as of November 7, 2025.